Hippo Holdings Inc. — Form 8-K Summary
Business context and reporting period
Hippo Holdings Inc. filed a Current Report on Form 8-K dated July 19, 2022. The filing concerns a New York Stock Exchange continued-listing deficiency and a proposed reverse stock split. It does not report quarterly or annual operating results.
Financial metrics and liquidity
The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.
Material changes and listing status
- Hippo received notice from the NYSE that its common stock did not satisfy NYSE Section 802.01C because its average closing price was below $1.00 per share over 30 consecutive trading days.
- The notice had no immediate effect on the listing or trading of Hippo common stock, subject to compliance with other NYSE requirements.
- Hippo was required to respond to the NYSE within ten business days regarding its intent to cure the deficiency.
- The company generally had six months from receipt of the notice to regain compliance, with a possible NYSE extension. Compliance requires a closing price of at least $1.00 and a 30-trading-day average closing price of at least $1.00 on the last trading day of a calendar month during the cure period.
Outlook, proposed actions, and risks
- Hippo planned a special stockholder meeting for August 31, 2022; holders of record as of July 18, 2022 were eligible to vote.
- Stockholders were expected to vote on a reverse stock split proposal with a ratio between 1-for-20 and 1-for-30, to be selected by the board or a board committee.
- The proposal also contemplated reducing the authorized shares of capital stock proportionately.
- The board stated that it currently intended to implement the reverse split if approved, unless it determined that the action would not help maintain NYSE listing or would not be in the best interests of the company and its stockholders.
- Failure to regain compliance within the applicable cure period could result in delisting. The reverse split was proposed as a potential measure to address the minimum share-price requirement, but the filing does not guarantee that it would be effective.
Important facts for investors to verify
- Whether Hippo regained NYSE minimum-price compliance within the cure period or received an extension.
- Whether stockholders approved the reverse stock split and, if so, the final ratio implemented.
- Whether the NYSE initiated or completed any delisting process.
- The definitive proxy statement and subsequent SEC filings for voting results, implementation details, and updated financial condition.